PHL-DIVALPROEX TABLET (ENTERIC-COATED)

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Beli sekarang

Download Ciri produk (SPC)
22-02-2013

Bahan aktif:

VALPROIC ACID (DIVALPROEX SODIUM)

Boleh didapati daripada:

PHARMEL INC

Kod ATC:

N03AG01

INN (Nama Antarabangsa):

VALPROIC ACID

Dos:

125MG

Borang farmaseutikal:

TABLET (ENTERIC-COATED)

Komposisi:

VALPROIC ACID (DIVALPROEX SODIUM) 125MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

100

Jenis preskripsi:

Prescription

Kawasan terapeutik:

MISCELLANEOUS ANTICONVULSANTS

Ringkasan produk:

Active ingredient group (AIG) number: 0112996004; AHFS:

Status kebenaran:

CANCELLED POST MARKET

Tarikh kebenaran:

2016-10-25

Ciri produk

                                PRODUCT MONOGRAPH
PR
PHL-DIVALPROEX
(Divalproex Sodium USP)
Enteric-Coated Tablets (125 mg, 250 mg, 500 mg)
Antiepileptic
PHARMEL INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of Revision:
February 22, 2013
Submission Control No: 162202
_phl-DIVALPROEX Product Monograph _
_Page 2 of 51_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................16
DRUG INTERACTIONS
..................................................................................................22
DOSAGE AND ADMINISTRATION
..............................................................................29
OVERDOSAGE
................................................................................................................32
ACTION AND CLINICAL PHARMACOLOGY
............................................................32
STORAGE AND STABILITY
..........................................................................................35
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................35
PART II: SCIENTIFIC INFORMATION
...............................................................................37
PHARMACEUTICAL INFORMATION
..........................................................................37
CLINICAL TRIALS
..........................................................................................................38
DETAILED PHARMACOLOGY
................................................
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Ciri produk Ciri produk Perancis 22-02-2013

Cari amaran yang berkaitan dengan produk ini